AUTHORS ' CONCLUSIONS Addition of ox and rolone to the GH therapy led to a modest increase in the final adult height of girls aged up to 18 years with TS .
BACKGROUND The final adult height of untreated girls aged up to 18 years with Turner syndrome ( TS ) is approximately 20 cm shorter compared with healthy females .
Treatment with growth hormone ( GH ) increases the adult height of people with TS .
The effects of adding the and rogen , ox and rolone , in addition to GH are unclear .
Therefore , we conducted this systematic review to investigate the benefits and harms of ox and rolone as an adjuvant therapy for people with TS treated with GH .
OBJECTIVES To assess the effects of ox and rolone on growth hormone-treated girls aged up to 18 years with Turner syndrome .
Long-term effects of previous oxandrolone treatment in adult women with Turner syndrome.
OBJECTIVE Short stature is a prominent feature of Turner syndrome ( TS ) , which is partially overcome by GH treatment . We have previously reported the results of a trial on the effect of ox and rolone ( Ox ) in girls with TS . Ox in a dose of 0.03 mg/kg per day ( Ox 0.03 ) significantly increased adult height gain , whereas Ox mg/kg per day ( 0.06 ) did not , at the cost of deceleration of breast development and mild virilization . The aim of this follow-up study in adult participants of the pediatric trial was to investigate the long-term effects of previous Ox treatment . DESIGN AND METHODS During the previous r and omized controlled trial , 133 girls were treated with GH combined with placebo ( Pl ) , Ox 0.03 , or Ox 0.06  from 8 years of age and estrogen from 12 years . Sixty-eight women ( Pl , n=23 ; Ox 0.03 , n=27 ; and Ox 0.06 , n=18 ) participated in the double-blind follow-up study ( mean age , 24.0 years ; mean time since stopping GH , 8.7 years ; and mean time of Ox/Pl use , 4.9 years ) . We assessed height , body proportions , breast size , virilization , and body composition . RESULTS Height gain ( final minus predicted adult height ) was maintained at follow-up ( Ox 0.03 10.2±4.9 cm , Ox 0.06 9.7±4.4 cm vs Pl 8.0±4.6 cm ) . Breast size , Tanner breast stage , and body composition were not different between groups . Ox-treated women reported more subjective virilization and had a lower voice frequency . CONCLUSION Ox 0.03 mg/kg per day has a beneficial effect on  adult height gain in TS patients . Despite previously reported deceleration of breast development during Ox 0.03 treatment , adult breast size is not affected . Mild virilization persists in only a small minority of patients . The long-term evaluation indicates that Ox 0.03 treatment is effective and safe
AUTHORS ' CONCLUSIONS Addition of ox and rolone to the GH therapy led to a modest increase in the final adult height of girls aged up to 18 years with TS .
BACKGROUND The final adult height of untreated girls aged up to 18 years with Turner syndrome ( TS ) is approximately 20 cm shorter compared with healthy females .
Treatment with growth hormone ( GH ) increases the adult height of people with TS .
The effects of adding the and rogen , ox and rolone , in addition to GH are unclear .
Therefore , we conducted this systematic review to investigate the benefits and harms of ox and rolone as an adjuvant therapy for people with TS treated with GH .
OBJECTIVES To assess the effects of ox and rolone on growth hormone-treated girls aged up to 18 years with Turner syndrome .